A61K36/23

METHOD FOR TRANSFORMING AN ESSENTIAL OIL

The invention relates to a method for transforming an essential oil, an essential oil fraction obtained in said manner, combinations comprising the essential fraction obtained in said manner and an antibiotic or an antifungal and the use thereof as a medicament in particular the use thereof in the prevention or treatment of infectious bacterial or fungal diseases.

METHOD FOR TRANSFORMING AN ESSENTIAL OIL

The invention relates to a method for transforming an essential oil, an essential oil fraction obtained in said manner, combinations comprising the essential fraction obtained in said manner and an antibiotic or an antifungal and the use thereof as a medicament in particular the use thereof in the prevention or treatment of infectious bacterial or fungal diseases.

Process to enhance the bioactivity of Ashwagandha extracts
11638738 · 2023-05-02 ·

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

Process to enhance the bioactivity of Ashwagandha extracts
11638738 · 2023-05-02 ·

The invention relates to an extract of Ashwagandha that exhibit enhanced bioactivity and bioavailability comprising of enriched withanolide glycosides and saponins; with negligible amount of alkaloids, withanolide aglycones and oligosaccharides. The extract as disclosed prepared from root, stems, leaves and whole plant of Ashwagandha further shows improved immunomodulatory activity, anti-inflammatory activity, anti stress activity, antidiabetic activity and sleep quality. The disclosure also provides a method of improving bioactivity of withanolide glycosides even at lower doses, by the administration of an enteric coated formulation of extract of Ashwagandha to humans. The enteric coating protects the composition from hydrolysis in the acidic environment of the stomach to release the withanolide glycoside in neutral/alkaline pH in gastrointestinal tract (GIT) thus enhancing the absorption. Further the process of preparation of the extract of Ashwagandha enriched with withanolide glycosides and saponins are disclosed along with various formulations.

Composition for ameliorating psoriasis symptoms containing extract of <i>Sphallerocarpus gracilis</i>

Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a Musan box (Sphallerocarpus gracilis) extract or a fraction thereof as an active ingredient.

Composition for ameliorating psoriasis symptoms containing extract of <i>Sphallerocarpus gracilis</i>

Disclosed is a composition for ameliorating, preventing or treating an autoimmune skin disease, containing a Musan box (Sphallerocarpus gracilis) extract or a fraction thereof as an active ingredient.

COMBINATIONS OF NANOPARTICLE-ENCAPSULATED CARGO ENTITIES AND METHODS FOR MAKING AND USING SAME

Combinations of nanoparticle-encapsulated cargo entities and methods of making and using same.

COMBINATIONS OF NANOPARTICLE-ENCAPSULATED CARGO ENTITIES AND METHODS FOR MAKING AND USING SAME

Combinations of nanoparticle-encapsulated cargo entities and methods of making and using same.

Risk mitigation of infectious disease transmission from incidental and intimate contact using atomic scale molecular disruption and biocidal halo-fullerenes delivered via topical, flushing and enteral mechanisms

The present invention pertains to quantum-scale biocidal particles and chemical reactions that disrupt and eviscerate microbial matter by combining aqueous and dry components. As halo-fullerene activation requires volatile excitation to mix, contact and collide so as to rupture microbial matter, atomic scale chemical reactions impart the requisite movement of engineered halo-fullerenes to destroy bacterial, fungal and viral matter upon contact. The present invention includes two primary mechanisms: an excitation chemistry and biocidal, hydrophobic halo-fullerenes. Upon aqueous exposure, the dry composition initiates a chemical reaction that activates biocidal halo-fullerenes to disrupt biologic surfaces in topical applications. The object of the present invention is a shelf stable, pre-packaged wiping material or dry packet for rehydration with broad spectrum antimicrobial activity. In one example, a matrix or wipe material would be comprised of densely packed and highly concentrated halo-fullerenes and a chemical reaction stimulant. When activated upon aqueous exposure, it would relax water molecules, alter hydrogen binding, and disrupt adhesion and cohesion forces that characterize surface tensions. These dynamics would then isolate sebaceous substances and free oxygen radicals, along with outgassing of carbon dioxide. The chemical reaction stimulant thus transfers energy and hyperactivates otherwise inert halo-fullerenes to form a biocidal composition. Broader utilities range from topical cleansing for personal hygiene, as well as various clinical and surgical procedures, as surgical and prophylactic lavage and rinse solutions, and enteral formulations as a hypertonic renal flush combined with short-acting diuresis. The halo-fullerene and hypertonic renal flush would cause osmotic cellular outflow, mitigate cellular microbial uptake and initial seroconversion and bloodborne events, while a botanical diuretic agent would facilitate systemic prophylaxis or treatment of UTIs.

Risk mitigation of infectious disease transmission from incidental and intimate contact using atomic scale molecular disruption and biocidal halo-fullerenes delivered via topical, flushing and enteral mechanisms

The present invention pertains to quantum-scale biocidal particles and chemical reactions that disrupt and eviscerate microbial matter by combining aqueous and dry components. As halo-fullerene activation requires volatile excitation to mix, contact and collide so as to rupture microbial matter, atomic scale chemical reactions impart the requisite movement of engineered halo-fullerenes to destroy bacterial, fungal and viral matter upon contact. The present invention includes two primary mechanisms: an excitation chemistry and biocidal, hydrophobic halo-fullerenes. Upon aqueous exposure, the dry composition initiates a chemical reaction that activates biocidal halo-fullerenes to disrupt biologic surfaces in topical applications. The object of the present invention is a shelf stable, pre-packaged wiping material or dry packet for rehydration with broad spectrum antimicrobial activity. In one example, a matrix or wipe material would be comprised of densely packed and highly concentrated halo-fullerenes and a chemical reaction stimulant. When activated upon aqueous exposure, it would relax water molecules, alter hydrogen binding, and disrupt adhesion and cohesion forces that characterize surface tensions. These dynamics would then isolate sebaceous substances and free oxygen radicals, along with outgassing of carbon dioxide. The chemical reaction stimulant thus transfers energy and hyperactivates otherwise inert halo-fullerenes to form a biocidal composition. Broader utilities range from topical cleansing for personal hygiene, as well as various clinical and surgical procedures, as surgical and prophylactic lavage and rinse solutions, and enteral formulations as a hypertonic renal flush combined with short-acting diuresis. The halo-fullerene and hypertonic renal flush would cause osmotic cellular outflow, mitigate cellular microbial uptake and initial seroconversion and bloodborne events, while a botanical diuretic agent would facilitate systemic prophylaxis or treatment of UTIs.